Scientists discover why Ozempic and Wegovy weight loss eventually plateaus
2 Articles
2 Articles
Scientists discover why Ozempic and Wegovy weight loss eventually plateaus
New NIH research reveals that semaglutide sparks different responses inside appetite-controlling brain cells, offering fresh insight into why GLP-1 weight-loss drugs don’t work the same for everyone. Scientists also found a possible way to extend the drugs’ effects, potentially helping patients push past weight-loss plateaus.
Researchers at the National Institutes of Health (NIH) have identified new mechanisms that explain why GLP-1-based weight-loss medications, such as semaglutide, show variations in results among patients and frequently reach a plateau in effectiveness. The study, published in the scientific journal Nature Reviews Endocrinology, reveals details about how these medications affect brain cells that control appetite. Cellular mechanisms of semaglutide…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
